Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
208 hedge funds and large institutions have $3.11B invested in Array Biopharma Inc in 2018 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 77 increasing their positions, 70 reducing their positions, and 35 closing their positions.
63% more call options, than puts
Call options by funds: $22.2M | Put options by funds: $13.7M
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
10% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 70
6% less capital invested
Capital invested by funds: $3.31B → $3.11B (-$204M)
7% less funds holding
Funds holding: 223 → 208 (-15)
37% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.5M |
| 2 |
Millennium Management
New York
|
+$32.4M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$24.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$19.2M |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$17.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13.5M |
| 2 |
Morgan Stanley
New York
|
-$10.1M |
| 3 |
Renaissance Technologies
New York
|
-$9.07M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.61M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.6M |
ARRY Hedge Fund Activity: Q3 2018 in Review
208 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2018, worth a combined $3.11B — down 6.1% from $3.31B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ARRY and 22 opened new positions — a net loss of 13 holders — while 70 trimmed existing stakes and 77 added.
The largest buyer was Fidelity Investments, adding an estimated $41.5M. The largest seller was Vanguard Group, cutting an estimated $13.5M.
- 208 institutional investors held Array Biopharma Inc (ARRY) as of Q3 2018, down from 223 in Q2 2018.
- Funds reported $3.11B of Array Biopharma Inc stock for Q3 2018, down 6.1% quarter-over-quarter.
- 22 funds opened new Array Biopharma Inc positions in Q3 2018 and 35 closed out, a net change of -13 holders.
- The largest Array Biopharma Inc buyer in Q3 2018 was Fidelity Investments, an estimated $41.5M added.
- The largest Array Biopharma Inc seller in Q3 2018 was Vanguard Group, an estimated $13.5M sold.
Based on aggregated 13F filings for Q3 2018.